Dr. Bruno Paiva
Co-director of the Flow Cytometry Platform.
Co-director of the Monoclonal Gammopathies Research Laboratory.
Preferential dedication to multidimensional flow cytometry analysis of hematological malignancies.
Graduated in Pharmacy in 2007 from the University of Coimbra, Portugal.
Master in Cancer Biology in 2009 at the University Hospital of Salamanca. University of Salamanca. Cancer Research Centre.
Doctor of Medicine in 2011 by the University of Salamanca.
He has been PI or Co-PI in 12 R&D projects funded through competitive calls from public or private entities, and has established more than 15 R&D collaboration agreements with companies such as Amgen, Becton Dickinson, BMS-Celgene, Miltenyi, Janssen, Roche, Sanofi and Takeda.
His research laboratory has been at the core of more than 20 national and international clinical trials in multiple myeloma and acute myeloid leukemia.
AREAS OF INTEREST
His research objectives are intrinsically related to the dual nature of his clinical and research laboratory: to provide state-of-the-art biomarkers for laboratory diagnostics through intensive basic and translational research.
He prioritizes its research in monoclonal gammopathies such as multiple myeloma (MM), light chain amyloidosis (AL) or Waldenstöm's macroglobulinemia (WM), and such research can be classified into five well-defined areas:
- Pathogenesis of MM, AL and WM.
- Risk of transformation in non-IgM and IgM MGUS
- Circulating tumor cells (CTCs)
- Minimal residual disease (MRD)
- Immune monitoring
His laboratory is now escalating our translational research program into other hematological malignancies such as acute myeloid leukemia.
As an educator
Visiting Professor in the Master of Biomedical Research and Biomedical Engineering at the Universidad de Navarra.
Organizer of numerous practical courses on immunophenotyping by flow cytometry.
As a researcher
With 13 years of research career, he is author in 150 publications, being first author in 37, last author and/or corresponding author in 15. Among them, there are several publications in the best journals such as N Engl J Med (n = 1), Nat Med (n = 1), Cancer Cell (n = 2), Lancet Oncol (n = 4) and J Clin Oncol (n = 4), and a high number of publications in the two most important journals of Hematology: Blood (n = 26) and Leukemia (n = 23). More than 90% of the publications are in Q1 of their respective specialty.
His publications have more than 5,200 citations (without self-citations) and an average of 51 citations per publication.
Frequent invited speaker at the most relevant international congresses in the field of Hematology and Flow Cytometry (~20/year).
I have been awarded with numerous recognitions, including the Bart Barlogie Young Investigator Award for outstanding research developed in multiple myeloma, and The Future Leaders in Hematology Award of the 2015 Celgene Awards for Clinical Research in Haematology.
Latest scientific publications
- Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma Mar 16, 2023 | Magazine: Nature Medicine
- Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia Oct 14, 2022 | Magazine: Blood Advances